Human CYP Panel
Accelerate drug metabolism screening with our Human CYP Panel. Aminoverse offers a curated selection of eight major human cytochrome P450 enzymes CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP2D6, and CYP3A enabling efficient assessment of metabolic pathways and CYP-mediated transformations.
Cytochrome P450 monooxygenases (CYPs) are a heme-containing superfamily of enzymes that catalyze the activation of molecular oxygen to perform mixed-function oxidations. Relying on NAD(P)H for electron regeneration, these biocatalysts facilitate complex transformations—including C-hydroxylation, N-, O-, and S-dealkylation, and epoxidation—on diverse substrates such as xenobiotics, steroids, and fatty acids. Their ability to functionalize non-activated C-H bonds provides a precise alternative to traditional chemical oxidation, which often lacks the regioselectivity required for complex molecular scaffolds.
The P450 Panel consists of 8 major human isoforms (1A1, 1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) recombinantly expressed in Komagataella phaffii (Pichia pastoris). Supplied as whole-cell biocatalysts, these enzymes cover the primary Phase I metabolic pathways responsible for the biotransformation of a large proportion of marketed small-molecule drugs. This standardized, ready-to-screen format is designed for high-fidelity applications in pharmacogenetics, bioactivation studies, and drug–drug interaction (DDI) assessments, providing the predictive data necessary for informed decision-making during lead optimization.
Validated for both drug metabolism and specialty chemical synthesis, this panel enables the efficient production of Phase I metabolites required for MIST (Metabolites in Safety Testing) compliance. The platform is mechanistically complementary to unspecific peroxygenases and KGOs, extending the accessible substrate scope for biocatalytic innovation. Any isoform identified during parallel screening can be scaled to kilogram quantities or further optimized via protein engineering, ensuring a seamless transition from early-stage discovery to process development in the pharmaceutical and fine chemical sectors.
Check out our other enzyme products
Online Inquiry